Reuters
German Chancellor Olaf Scholz said he was committed to supporting the pharmaceuticals sector with tax advantages for research and cutting red tape for trials at a ceremony with Merck, which is investing 1.5 billion euros ($1.61 billion) in Germany. The drugmaker plans to use its new life sciences Advanced Research Centre in the western city of Darmstadt, which it is spending 300 million euros on, to develop services and digital platforms to help scientists work more effectively. Scholz said he wanted Germany to build on a 2.3 billion euro investment by Eli Lilly in the western town of Alzey and other development plans by Novo Nordisk, BioNTech , AbbVie and Roche for Europe's biggest economy.